Mark Schoenberg Sells 5,162 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) Stock

UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) insider Mark Schoenberg sold 5,162 shares of the business's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $7.37, for a total transaction of $38,043.94. Following the sale, the insider now directly owns 153,378 shares of the company's stock, valued at approximately $1,130,395.86. This represents a 3.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

UroGen Pharma Trading Up 44.8%

Shares of URGN traded up $3.27 during midday trading on Thursday, hitting $10.57. The stock had a trading volume of 16,053,962 shares, compared to its average volume of 925,969. UroGen Pharma Ltd. has a fifty-two week low of $3.42 and a fifty-two week high of $20.70. The business has a 50-day simple moving average of $8.47 and a two-hundred day simple moving average of $10.08. The firm has a market cap of $487.35 million, a P/E ratio of -3.36 and a beta of 0.40. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The company had revenue of $20.25 million for the quarter, compared to analyst estimates of $22.71 million. As a group, equities analysts forecast that UroGen Pharma Ltd. will post -3.12 EPS for the current year.

Institutional Investors Weigh In On UroGen Pharma

Institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC acquired a new stake in shares of UroGen Pharma during the 4th quarter valued at about $1,472,000. Lazard Asset Management LLC acquired a new stake in UroGen Pharma in the fourth quarter valued at approximately $67,000. Janus Henderson Group PLC acquired a new stake in UroGen Pharma in the fourth quarter valued at approximately $149,000. ProShare Advisors LLC acquired a new stake in shares of UroGen Pharma in the 4th quarter valued at $137,000. Finally, Bank of New York Mellon Corp lifted its position in shares of UroGen Pharma by 7.3% in the fourth quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company's stock worth $1,001,000 after buying an additional 6,430 shares during the last quarter. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently commented on URGN shares. HC Wainwright lowered shares of UroGen Pharma from a "buy" rating to a "neutral" rating in a research report on Thursday, May 22nd. Scotiabank started coverage on UroGen Pharma in a research note on Wednesday, April 16th. They set a "sector outperform" rating and a $23.00 target price for the company. D. Boral Capital reaffirmed a "buy" rating and set a $25.00 target price on shares of UroGen Pharma in a research note on Thursday. The Goldman Sachs Group reduced their price objective on shares of UroGen Pharma from $16.00 to $3.00 and set a "neutral" rating for the company in a research report on Thursday, May 22nd. Finally, LADENBURG THALM/SH SH began coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They set a "buy" rating and a $31.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $23.14.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.